Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 24586226)

1.

TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial.

Dreno B, Urosevic-Maiwald M, Kim Y, Guitart J, Duvic M, Dereure O, Khammari A, Knol AC, Derbij A, Lusky M, Didillon I, Santoni AM, Acres B, Bataille V, Chenard MP, Bleuzen P, Limacher JM, Dummer R.

PLoS One. 2014 Feb 24;9(2):e83670. doi: 10.1371/journal.pone.0083670. eCollection 2014.

2.

Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas.

Dummer R, Hassel JC, Fellenberg F, Eichmüller S, Maier T, Slos P, Acres B, Bleuzen P, Bataille V, Squiban P, Burg G, Urosevic M.

Blood. 2004 Sep 15;104(6):1631-8. Epub 2004 May 25.

3.

Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas.

Dummer R, Eichmüller S, Gellrich S, Assaf C, Dreno B, Schiller M, Dereure O, Baudard M, Bagot M, Khammari A, Bleuzen P, Bataille V, Derbij A, Wiedemann N, Waterboer T, Lusky M, Acres B, Urosevic-Maiwald M.

Mol Ther. 2010 Jun;18(6):1244-7. doi: 10.1038/mt.2010.52. Epub 2010 Apr 6.

4.

Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042.

Accart N, Urosevic-Maiwald M, Dummer R, Bataille V, Kehrer N, Niculescu C, Limacher JM, Chenard MP, Bonnefoy JY, Rooke R.

J Transl Med. 2013 Sep 25;11:226. doi: 10.1186/1479-5876-11-226.

6.
7.

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R.

Oncologist. 2007 Oct;12(10):1247-52.

8.

Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.

Wollina U, Looks A, Meyer J, Knopf B, Koch HJ, Liebold K, Hipler UC.

J Am Acad Dermatol. 2001 Feb;44(2):253-60.

PMID:
11174383
9.

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M.

J Clin Oncol. 2007 Jul 20;25(21):3109-15. Epub 2007 Jun 18.

10.

Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.

de Masson A, Guitera P, Brice P, Moulonguet I, Mouly F, Bouaziz JD, Battistella M, Madelaine I, Roux J, Ram-Wolff C, Cayuela JM, Bachelez H, Bensussan A, Michel L, Bagot M.

Br J Dermatol. 2014 Mar;170(3):720-4. doi: 10.1111/bjd.12690.

PMID:
24438061
11.

Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study.

Dummer R, Krasovec M, Röger J, Sindermann H, Burg G.

J Am Acad Dermatol. 1993 Dec;29(6):963-70.

PMID:
8245262
12.

Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma.

Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A, Rook AH, Mark LA, Pinter-Brown L, Hamid O, Lin B, Bian Y, Boye M, Day JM, Rosen ST.

Leuk Lymphoma. 2011 Aug;52(8):1474-80. doi: 10.3109/10428194.2011.572265. Epub 2011 Jun 8.

PMID:
21649541
13.

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T.

J Clin Oncol. 2013 Jan 1;31(1):104-10. doi: 10.1200/JCO.2012.43.7285. Epub 2012 Oct 29.

14.

Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.

Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A.

J Clin Oncol. 2010 Apr 10;28(11):1870-7. doi: 10.1200/JCO.2009.26.2386. Epub 2010 Mar 8.

15.

Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.

Bohmeyer J, Stadler R, Kremer A, Nashan D, Muche M, Gellrich S, Luger T, Sterry W.

J Dtsch Dermatol Ges. 2003 Oct;1(10):785-9.

PMID:
16281814
16.

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.

Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH.

J Clin Oncol. 2010 Oct 10;28(29):4485-91. doi: 10.1200/JCO.2010.28.9066. Epub 2010 Aug 9.

17.

Treatment of primary cutaneous B-cell lymphoma with rituximab.

Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L.

J Am Acad Dermatol. 2005 May;52(5):847-53.

PMID:
15858476
18.

Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma.

Peñate Y, Hernández-Machín B, Pérez-Méndez LI, Santiago F, Rosales B, Servitje O, Estrach T, Fernández-Guarino M, Calzado L, Acebo E, Gallardo F, Salar A, Izu R, Ortiz-Romero PL, Pujol RM, Fernández-de-Misa R.

Br J Dermatol. 2012 Jul;167(1):174-9. doi: 10.1111/j.1365-2133.2012.10902.x.

PMID:
22356294
19.

Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.

Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, Vonderheid EC.

Blood. 1999 Aug 1;94(3):902-8.

20.

Treatment of indolent primary cutaneous B-cell lymphomas with subcutaneous interferon-alfa.

Vandersee S, Terhorst D, Humme D, Beyer M.

J Am Acad Dermatol. 2014 Apr;70(4):709-15. doi: 10.1016/j.jaad.2013.11.019. Epub 2014 Jan 13.

PMID:
24433874
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk